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Background: Over the past 2 decades, the development of cardiac allograft vasculopathy(CAV) in heart transplant(HTx) patients(pts) has 
not significantly changed. Randomized clinical trials comparing cyclosporine(CSA) and tacrolimus(TAC)-based regimens have not demonstrated 
significant differences in CAV development, but followup time has been short(2 yrs). Mycophenolate(MMF) has been shown in a large randomized 
trial to decrease first yr intimal thickening in HTx pts compared to azathioprine (both groups with CSA). TAC/MMF vs CSA/MMF in the 3-Arm Trial 
significantly reduced rejection but followup time was insufficient to assess for CAV. To assess for a possible CAV benefit, we reviewed our pts 
maintained on TAC/MMF vs CSA/MMF for development of CAV over 5 yrs. 
methods: Between 1994-2010, we evaluated 728 HTx pts. CAV was defined as any angiographic stenosis ≥ 30%. Pts were divided into those 
maintained on CSA/MMF(n = 273) and TAC/MMF(n = 455). 5 yr actuarial survival, freedom from CAV and freedom from non-fatal major adverse 
cardiac events(NF-MACE) were assessed. 
results:  Pts treated with TAC/MMF vs CSA/MMF had significantly greater freedom from CAV(81% vs 74%, p=0.044). Survival and NF-MACE were 
similar (table). CAV severity according to the ISHLT CAV nomenclature was similar in CSA/MMF vs TAC/MMF (CAV1: 59% vs 65%, p = 0.57; CAV2: 
19% vs. 14%, p = 0.52; CAV3: 22% vs 21%, p = 0.92). 
conclusion:  TAC/MMF appears to have a beneficial effect in decreasing the incidence of CAV post-HTx. 
Outcomes
CSA/MMF
(N = 273)
TAC/MMF
(N = 455)
p-value
5-Year Actuarial Survival 78% 83% 0.133
5-Year Freedom from CAV 74% 81% 0.044
5-Year Freedom from NF-MACE 84% 84% 0.868
1-Year Freedom from Any-Treated Rejection 88% 85% 0.349
